However, in a phase I clinical of KRAS mutant non-small cell lung cancer patients, it was found that combination Tra/Pon treatment was associated with cardiovascular (CV) and bleeding toxicities34. This evidence concerns the gene KRAS and non-small cell lung carcinoma.